| PubMed | Title | Journal | Year | Linked by |
|---|
| PMID 40785174 | A Paradigm Shift in Hemophilia Care: The Promise of Gene Therapy. | Current gene therapy | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 41274843 | Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms. | Blood reviews | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 41381305 | Liver dysfunction in AAV-mediated Hemophilia B gene therapy: Mechanisms and management strategies. | Blood reviews | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 41448545 | Overview of gene therapy for hemophilia: questions and answers to navigate the innovation. | Journal of thrombosis and haemostasis : JTH | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 41496894 | CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges. | Molecular therapy. Nucleic acids | 2026 | name in abstract: Hemgenix |
| PMID 41549917 | Balancing Promise and Peril: Hemophilia Gene Therapy Insights. | IUBMB life | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 41624239 | Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial. | Research and practice in thrombosis and haemostasis | 2026 | name in title: etranacogene dezaparvovec |
| PMID 41756540 | Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial. | Research and practice in thrombosis and haemostasis | 2026 | name in title: etranacogene dezaparvovec |
| PMID 41773269 | Current Status of Clinical Gene Therapy for Hemophilia and Globin Disorders. | Journal of blood medicine | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 41938187 | Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B. | The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians | 2026 | name in title: etranacogene dezaparvovec |
| PMID 41988906 | Bringing Gene Therapy Into Real World Clinical Practice. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 42322300 | Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec. | CPT: pharmacometrics & systems pharmacology | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42432779 | Vulnerability, protection and fairness: ethical and regulatory limits in small-N gene therapy trials. | Trials | 2026 | name in abstract: Hemgenix |
| PMID 42459106 | Etranacogene dezaparvovec in hemophilia B: early safety insights. | Recenti progressi in medicina | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42509646 | Correction to "Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec". | CPT: pharmacometrics & systems pharmacology | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42676001 | Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 42750232 | Treatment With Etranacogene Dezaparvovec in a Renal Transplant Recipient With Hemophilia B on Concomitant Systemic Immunosuppressive Therapy. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42762467 | Biphasic Transaminitis During Corticosteroid Tapering After Etranacogene Dezaparvovec Gene Therapy for Haemophilia B: Management Lessons From the First Spanish Case. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42829928 | Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden. | Journal of medical economics | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42830788 | Corrigendum to 'Etranacogene dezaparvovec in people with hemophilia B with preexisting adeno-associated virus 5 neutralizing antibodies: 4-year subgroup results from the HOPE-B trial': [RPTH, 103360, January 2026, Volume 10, Issue 1]. | Research and practice in thrombosis and haemostasis | 2026 | name in title: etranacogene dezaparvovec |
| PMID 42837422 | The Genomic Equity Accessibility Framework (GEAF): A dimensionally consistent framework for modeling affordability and equity in genomic and regenerative therapies. | PloS one | 2026 | name in abstract: Hemgenix |
| PMID 42932029 | Financing High-Cost Gene Therapy Under Clinical Uncertainty: Assessing Budget Impact of Reimbursement Models for Hemgenix® in Hemophilia B in Sweden. | Applied health economics and health policy | 2026 | name in title: Hemgenix |
| PMID 42947409 | Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience. | Haemophilia : the official journal of the World Federation of Hemophilia | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 42976908 | Patient-Relevant Questions on Gene Therapy for Haemophilia. | Hamostaseologie | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 42984386 | Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products. | Haematologica | 2026 | name in abstract: etranacogene dezaparvovec |
| PMID 39368017 | Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability. | PharmacoEconomics | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 39623116 | Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA. | Applied health economics and health policy | 2025 | name in title: etranacogene dezaparvovec |
| PMID 39868419 | Gene-ius at work: Hemophilia B treatment enters a new era. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 40156191 | The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 40488175 | Gene-based therapies for hemophilia. | Research and practice in thrombosis and haemostasis | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 40534246 | Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. | Haemophilia : the official journal of the World Federation of Hemophilia | 2025 | name in title: etranacogene dezaparvovec |
| PMID 40868273 | Curative Therapies for Hemophilias and Hemoglobinopathies in Adults: Immune, Gene, and Stem Cell Approaches in a Global Context. | Biomedicines | 2025 | name in abstract: Hemgenix |
| PMID 40916408 | Advances in Gene Therapy Clinical Trials for Hemophilia Care. | Current gene therapy | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 40969675 | Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study. | Molecular therapy. Methods & clinical development | 2025 | name in title: etranacogene dezaparvovec |
| PMID 41229950 | Role of Pharmacy Professionals in Gene Therapy Based on Adeno-Associated Viruses: Treatment of Hemophilia as a Template of Care. | The Canadian journal of hospital pharmacy | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 41348030 | Deconstructing gene therapy in hemophilia for the clinician. | Hematology. American Society of Hematology. Education Program | 2025 | name in abstract: etranacogene dezaparvovec |
| PMID 37902714 | Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B. | Haemophilia : the official journal of the World Federation of Hemophilia | 2024 | name in title: etranacogene dezaparvovec |
| PMID 37978816 | Valoctocogene Roxaparvovec and Etranacogene Dezaparavovec: Novel Gene Therapies for Hemophilia A and B. | The Annals of pharmacotherapy | 2024 | name in abstract: Hemgenix |
| PMID 37989969 | Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. | PharmacoEconomics | 2024 | name in abstract: etranacogene dezaparvovec |
| PMID 38384245 | Recent developments in gene therapy research in India. | Journal of biosciences | 2024 | name in abstract: Hemgenix |
| PMID 38520664 | Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. | PharmacoEconomics - open | 2024 | name in title: etranacogene dezaparvovec |
| PMID 38592711 | Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. | Blood advances | 2024 | name in title: etranacogene dezaparvovec |
| PMID 38625717 | Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States. | Journal of managed care & specialty pharmacy | 2024 | name in title: etranacogene dezaparvovec |
| PMID 38708771 | Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States. | Journal of medical economics | 2024 | name in title: etranacogene dezaparvovec |
| PMID 38830504 | Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity. | Drug discovery today | 2024 | name in abstract: etranacogene dezaparvovec |
| PMID 38995136 | [Haemophilia B therapy: impact of the reimbursability of a long-acting recombinant factor on pharmaceutical expenditure in Italy]. | Epidemiologia e prevenzione | 2024 | name in abstract: etranacogene dezaparvovec |
| PMID 39088338 | The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B. | Journal of managed care & specialty pharmacy | 2024 | name in title: etranacogene dezaparvovec |
| PMID 39173877 | Gene therapy for people with hemophilia B: a proposed care delivery model in Italy. | Journal of thrombosis and haemostasis : JTH | 2024 | name in abstract: etranacogene dezaparvovec |
| PMID 39339243 | Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B. | Pharmaceutics | 2024 | name in abstract: etranacogene dezaparvovec |
| PMID 39340327 | Value contribution of etranacogene dezaparvovec gene therapy in moderately severe and severe haemophilia B through multi-criteria decision analysis. | Haemophilia : the official journal of the World Federation of Hemophilia | 2024 | name in title: etranacogene dezaparvovec |
| PMID 36285399 | Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B. | Current medical research and opinion | 2023 | name in title: etranacogene dezaparvovec |
| PMID 36651790 | Hemgenix - A gene therapy for hemophilia B. | The Medical letter on drugs and therapeutics | 2023 | name in title: Hemgenix |
| PMID 36774218 | New Drug Capsule: etranacogene dezaparvovec. | Clinical therapeutics | 2023 | name in title: etranacogene dezaparvovec |
| PMID 36799758 | [A long-awaited - but prohibitively expensive - therapy]. | Medecine sciences : M/S | 2023 | name in abstract: Hemgenix |
| PMID 36802324 | Etranacogene Dezaparvovec: First Approval. | Drugs | 2023 | name in title: etranacogene dezaparvovec |
| PMID 37353081 | Hemophilia gene therapy: first, do no harm. | Journal of thrombosis and haemostasis : JTH | 2023 | name in abstract: etranacogene dezaparvovec |
| PMID 37490225 | Evaluating Gene Therapy as a Potential Paradigm Shift in Treating Severe Hemophilia. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2023 | name in abstract: etranacogene dezaparvovec |
| PMID 37672530 | Hemophilia Gene Therapy: The End of the Beginning? | Human gene therapy | 2023 | name in abstract: etranacogene dezaparvovec |
| PMID 37882214 | Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B. | Expert review of hematology | 2023 | name in title: etranacogene dezaparvovec |
| PMID 37962325 | Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). | Expert opinion on biological therapy | 2023 | name in title: etranacogene dezaparvovec |
| PMID 38462459 | Viral Vectors in Gene Replacement Therapy. | Biochemistry. Biokhimiia | 2023 | name in abstract: Hemgenix |
| PMID 36082993 | Liver Gene Therapy. | Human gene therapy | 2022 | name in abstract: etranacogene dezaparvovec |
| PMID 36485127 | Gene therapy for hemophilia. | Hematology. American Society of Hematology. Education Program | 2022 | name in abstract: etranacogene dezaparvovec |
| PMID 37181105 | Etranacogene dezaparvovec for hemophilia B gene therapy. | Therapeutic advances in rare disease | 2021 | name in title: etranacogene dezaparvovec |
| PMID 32777062 | Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv. 2019;3(21):3241-3247. | Blood advances | 2020 | name in title: etranacogene dezaparvovec |
| PMID 31276009 | Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs. | Molecular therapy. Methods & clinical development | 2019 | name in abstract: AMT-061 |
| PMID 31709273 | Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs. | Molecular therapy. Methods & clinical development | 2019 | name in abstract: AMT-061 |